NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients

(2018) Nele Boeckx et al.   Clinical Colorectal Cancer

Identification of Core Genes and Key Pathways via Integrated Analysis of Gene Expression and DNA Methylation Profiles in Bladder Cancer

(2018) Yongzhen Zhang et al.   MEDICAL SCIENCE MONITOR

Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses

(2018) Rikke Fredslund Andersen   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine

(2017) Maria Jeppesen et al.   PLoS One

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker

(2016) S. Garrigou et al.   CLINICAL CHEMISTRY

Methylated circulating tumor DNA in blood: power in cancer prognosis and response

(2016) Kristina Warton et al.   ENDOCRINE-RELATED CANCER

Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review

(2016) Bingsheng Li et al.   PLoS One

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Redundancy: A Critical Obstacle to Improving Cancer Therapy

(2015) O. Lavi   CANCER RESEARCH

Controls to validate plasma samples for cell free DNA quantification

(2015) Niels Pallisgaard et al.   CLINICA CHIMICA ACTA

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

Circulating Tumor DNA as a Liquid Biopsy for Cancer

(2014) E. Heitzer et al.   CLINICAL CHEMISTRY

Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer

(2013) Jean-Pierre Roperch et al.   BMC CANCER

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

(2013) Angela Esposito et al.   CANCER TREATMENT REVIEWS

Regorafenib for cancer

(2012) Dirk Strumberg et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology

(2012) Isabelle Baszanger   SOCIAL SCIENCE & MEDICINE

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE

Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature

(2010) Klaus Jung et al.   CLINICA CHIMICA ACTA

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER